Related references
Note: Only part of the references are listed.A real-world experience of combined treatment with romidepsin and azacitidine in patients with peripheral T-cell lymphoma.
Matko Kalac et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma
Matko Kalac et al.
BLOOD (2021)
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Lorenzo Falchi et al.
BLOOD (2021)
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
Sang Eun Yoon et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia
Sang Eun Yoon et al.
LANCET REGIONAL HEALTH-WESTERN PACIFIC (2021)
Multi-Center Phase II Study of Oral Azacitidine (CC-486) Plus CHOP As Initial Treatment for Peripheral T-Cell Lymphoma (PTCL)
Jia Ruan et al.
BLOOD (2020)
Practical Treatment Approach for Angioimmunoblastic T-Cell Lymphoma
Alison J. Moskowitz
JOURNAL OF ONCOLOGY PRACTICE (2019)
Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling
Yosaku Watatani et al.
LEUKEMIA (2019)
Angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome with mutations in TET2, DNMT3 and CUX1 - azacitidine induces only lymphoma remission
Magnus Tobiasson et al.
LEUKEMIA & LYMPHOMA (2019)
Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study
Owen A. O'Connor et al.
BLOOD (2019)
Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS
Gareth P. Gregory et al.
HEMASPHERE (2019)
Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology
Lei Qin et al.
FRONTIERS IN IMMUNOLOGY (2018)
Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma
Francois Lemonnier et al.
BLOOD (2018)
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma
Matthew A. Lunning et al.
BLOOD (2017)
Efficacy of 5-Azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma
Morgane Cheminant et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Somatic RHOA mutation in angioimmunoblastic T cell lymphoma
Mamiko Sakata-Yanagimoto et al.
NATURE GENETICS (2014)
Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome
Ellen K. Ritchie
CLINICAL INTERVENTIONS IN AGING (2012)
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
Audrey Simon et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Share Paper
